Readiness requires an accountable decision record—not just an enthusiastic sponsor. Include review of patient-facing claims: FDA warns telehealth companies against misleading statements about compounded products, their equivalence to approved medicines and their actual source. (fda.gov)
Answers stay in this session unless you choose to save. No account needed.
Evidence to attach: the approval record, monitoring calendar, escalation triggers and patient-communications review.
If you score 0–1: convene a cross-functional approval meeting before signature or renewal.
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs